TopFunds

Medpace

NASDAQ: MEDP

Stock price

618.47 USD

(+0%) TODAY

medical researchMedical - Diagnostics & ResearchInvestable Universe
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(0.3)
0.4
1
2
2.7
3.8
4.8
7.3
8.9
12.6
15.3
-
02Free cash flow per share
2
2.2
2.1
3.8
4.9
6
6.2
10.4
12.5
17.9
23.1
27.7%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
359.1
421.6
436.2
704.6
861
925.9
1,142
1,460
1,886
2,109
2,530
21.6%
06% Change
-
-
-
-
-
-
-
-
-
-
-
21.6%
07Cost of revenue
(202.7)
(249.5)
(261.5)
(489.1)
(615.3)
(647.2)
(814.2)
(1,028)
(1,361)
(1,453)
(1,770)
24.2%
08Gross profit
156.4
172.1
174.7
215.5
245.7
278.7
328.2
432.4
524.5
656.3
760.6
17.1%
09% Margin
43.6%
40.8%
40.1%
30.6%
28.5%
30.1%
28.7%
29.6%
27.8%
31.1%
30.1%
32.8% A
10Operating expenses
(135.8)
(119.6)
(109.8)
(114.5)
(118.4)
(111.7)
(129.5)
(153.7)
(187.7)
(209.4)
(225.7)
5.2%
11% of Revenue
(37.8)%
(28.4)%
(25.2)%
(16.3)%
(13.8)%
(12.1)%
(11.3)%
(10.5)%
(10)%
(9.9)%
(8.9)%
(16.7)% A
12Operating Income
20.6
52.5
64.9
101
127.3
167
198.6
278.7
336.8
446.9
534.9
38.5%
13Income tax expense
(0.8)
(8.5)
(17.8)
(20.8)
(24.4)
(23.1)
(20)
(37.5)
(52.9)
(71.5)
(91.3)
59.8%
14Net Income
(8.7)
13.4
39.1
73.2
100.4
145.4
181.8
245.4
282.8
404.4
451.1
-
15% Margin
(2.4)%
3.2%
9%
10.4%
11.7%
15.7%
15.9%
16.8%
15%
19.2%
17.8%
12% A
16Shares Outstanding
39.6
36.3
39.8
36.9
37.6
37.7
37.7
33.7
31.8
32
29.5
(2.9)%
17EPS Basic
(0.3)
0.4
1
2.1
2.8
4.1
5.1
7.6
9.2
13.1
15.6
-
18EPS Diluted
(0.3)
0.4
1
2
2.7
3.8
4.8
7.3
8.9
12.6
15.3
-
19EBITDA
89
99.5
111
139.8
150.5
186.6
223.1
308.1
362.5
505.2
570.5
20.4%
% Margin
24.8%
23.6%
25.4%
19.9%
17.5%
20.2%
19.5%
21.1%
19.2%
24%
22.6%
21.6% A
20Net Interest Income (expense)
(27.3)
(19.4)
(7.6)
(8.2)
(1.6)
0.3
(0.1)
(2.9)
(0.5)
25
-
-
21Net Debt / EBITDA
4.1
1.3
1.8
0.4
(0.5)
(0.8)
(1.4)
0.6
(0.2)
(1)
(0.6)
0.3 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
14.9
37.1
26.5
23.3
131.9
277.8
461.3
28.3
245.4
669.4
497
42%
23Short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
65.1
79.8
83.1
133.4
155.7
161
186.4
253.4
298.4
296.4
402.1
20%
25Other current assets
14.2
16.4
20.4
21.4
29.4
34.9
43.2
52.3
50
63.4
90.5
20.4%
26Inventory
2.9
0.3
-
-
-
-
-
-
-
-
-
-
27Total Current Assets
94.7
133.2
130
178.1
317
473.7
690.9
334
593.8
1,029
989.6
26.5%
Non-Current Assets
28Net property, plant & equipment
37.5
43.8
48.7
52.3
99.4
198.8
222.7
248.9
265.4
252.3
248.9
20.8%
29Long-term investments
-
-
-
-
-
-
-
-
-
-
-
-
30Other non-current assets
851.8
802.1
772
737.6
726.6
718.2
746.3
769.6
797.6
819.4
737
(1.4)%
31Total Non-Current Assets
889.3
845.9
820.7
789.8
826
917
969
1,019
1,063
1,072
985.8
1%
Total Assets
984
979.1
950.7
967.9
1,143
1,391
1,660
1,353
1,657
2,101
1,976
7.2%
LIABILITIES
Current Liabilities
32Accounts payable
8.7
10.9
16.7
16.7
22.4
26.6
25.7
33.1
31.9
32.5
28.1
12.4%
33Short-term debt
1.7
12.4
18.4
2.1
11
15.9
16.3
69.3
22.4
23.3
23.2
30.2%
34Other current liabilities
123.6
145.3
157.6
238.2
309.6
397.7
515.3
701.1
870.9
1,049
1,292
26.5%
35Total Current Liabilities
134
168.6
192.7
257
343
440.1
557.2
803.5
925.1
1,105
1,344
25.9%
Non-Current Liabilities
36Long-term debt
377.9
151.3
205.1
79.7
45.2
115.1
131
138.9
142.1
126.2
113.6
(11.3)%
37Other non-current liabilities
58.7
48.5
49.4
41.5
28.6
29.6
18.8
23.8
30.6
44.5
59
0.1%
38Total Non-Current Liabilities
436.6
199.8
254.5
121.2
73.8
144.8
149.8
162.6
172.7
170.8
172.7
(8.9)%
39Total Liabilities
570.6
368.4
447.2
378.2
416.8
584.9
707
966.1
1,098
1,275
1,516
10.3%
SHAREHOLDERS` EQUITY
40Common stock
0.3
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.3
0.3
0.3
(1.4)%
41Retained earnings / (deficit)
(23)
(9.6)
(120.4)
(41.5)
68.1
115.2
235
(359.8)
(221.6)
8.2
(460)
34.9%
42Accumulated other comprehensive income / (loss)
(2.6)
(3.7)
(0.7)
(2.5)
(2.7)
(0.1)
(4.8)
(12.4)
(10.1)
(14.7)
(4.9)
6.7%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
413.5
610.7
503.5
589.7
726.3
805.8
952.9
386.4
559
825.5
459.1
1.1%
45Total Liabilities and shareholders' Equity
984
979.1
950.7
967.9
1,143
1,391
1,660
1,353
1,657
2,101
1,976
7.2%
46Total Debt
379.5
163.6
223.5
81.8
56.2
131
147.2
208.1
164.5
149.5
136.9
(9.7)%
47Net Debt
364.7
126.5
197
58.5
(75.7)
(146.7)
(314.1)
179.9
(81)
(519.9)
(360.2)
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(8.7)
13.4
39.1
73.2
100.4
145.4
181.8
245.4
282.8
404.4
451.1
-
49Depreciation & amortization
69.5
58.1
46.5
38.8
23.2
19.5
21.1
22.3
26.3
29.3
28.1
(8.7)%
50Share-based compensation expense
22.3
9.8
4.5
6.5
20.7
13.8
14.5
21.4
20.5
25.5
34.8
4.5%
51Changes in working capital and other assets
2.7
10.4
7.3
38.1
57.5
80
45.9
98.9
103.7
149.7
199.2
53.8%
52Net cash flows from operating activities
85.9
91.7
97.4
156.6
201.9
258.7
263.3
388.1
433.4
608.8
713.2
23.6%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(6.5)
(13.5)
(11.7)
(16)
(17.9)
(31.3)
(28.3)
(36.9)
(36.6)
(36.5)
(31.4)
17.1%
54Purchases of investments / marketable securities
-
-
-
-
-
-
-
-
-
-
-
-
55Proceeds from maturities of marketable securities
-
-
-
-
-
-
-
-
-
-
-
-
56Other investing activities
-
0.1
(0.5)
(0.9)
(1.2)
0.1
(3.1)
(1.9)
2
8.2
0.2
20.7%
57Net cash flows from investing activities
(6.4)
(13.4)
(12.2)
(17)
(19.1)
(31.2)
(31.4)
(38.7)
(34.6)
(28.3)
(31.1)
17.1%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
0.6
173.6
(155.6)
-
-
(98.3)
(62.1)
(847.8)
(144)
(169.9)
(860.4)
-
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
(116.1)
(226.1)
57.6
(142.2)
(80.4)
-
-
50
(50)
-
-
-
61Other financing activities
(1)
(5.5)
0.1
0.6
6.5
16
17.6
22.1
11.4
15.9
-
-
62Net cash flows from financing activities
(116.5)
(58)
(97.8)
(141.6)
(73.9)
(82.3)
(44.5)
(775.8)
(182.6)
(154)
(860.4)
22.1%
63Increase (decrease) in cash and cash equivalents
(37.7)
19.7
(10.9)
(3.2)
108.6
145.8
183.5
(433)
217.2
424
(172.4)
16.4%
64Cash and equivalents, ending balance
17.7
37.4
26.5
23.3
131.9
277.8
461.3
28.3
245.4
669.4
497
39.6%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
79.4
78.2
85.7
140.6
184
227.3
235.1
351.2
396.7
572.3
681.9
24%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Medpace (MEDP) financial statements and performance

Explore Medpace (MEDP) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.